Human growth hormone deficiency (GHD) has an incidence of approximately 1/4,000 to 1/110,000 births. An unknown but significant proportion of cases are familial because up to 30% of those affected have an affected parent or child. Replacement therapy with GH derived by recombinant DNA techniques is expensive but necessary to avoid Creutzfeldt-Jakob disease caused by viral contamination of GH isolated from cadaver pituitaries. Arginine vasopressin (AVP) deficiency causes diabetes insipidus (DI) of which 1/50 human cases are familial. DI has significant associated morbidity and mortality and its treatment requires careful water, electrolyte and AVP replacement. In previous studies I have discovered the molecular basis of a variety of familial forms of GHD including gene deletions that arise through recombination, developed a PCR method to detect GH deletions and detected recessive and """"""""dominant-negative"""""""" mutations that affect alternative splicing of GH. I have mapped the locus for DI due to AVP deficiency and detected recurring """"""""dominant-negative"""""""" mutations that affect cleavage of AVP's signal peptide or AVP expression. My overall goals are to explore the five concepts that """"""""dominant-negative"""""""" mutations of AVP and GH1 are heterogeneous and probably have their effect at the protein level; alternative splicing differs qualitatively and quantitatively between normal and abnormal GH1 alleles due, in some cases, to mutations in stem loops in IVSs that are not splicing consensus sequences; analysis of mutant products should give insights to intracellular trafficking and secretion mechanisms, and less severe mutations may contribute to normal variations in growth. To achieve these goals I plan to determine the: 1) gene alterations causing autosomal recessive, autosomal dominant, X-linked and sporadic forms of isolated GHD, 2) mechanism(s) by which various gene alterations cause GHD, and 3) molecular basis of familial forms of DI that are associated with AVP deficiency. Characterization of the molecular basis of GH and AVP deficiency will provide insight to the 1) mechanisms of how derangement of genes for monomeric hormones cause autosomal recessive or dominant phenotypes, 2) pathogenesis of analogous """"""""dominant-recessive"""""""" endocrine disorders, 3) mechanisms of molecular and protein trafficking within cells, and 4) functional relationships between normal gene structure, function and homeostasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK035592-11A2
Application #
2139605
Study Section
Endocrinology Study Section (END)
Project Start
1984-08-01
Project End
1999-06-30
Budget Start
1995-07-20
Budget End
1996-06-30
Support Year
11
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Poling, Justin S; Phillips 3rd, John A; Cogan, Joy D et al. (2011) Pharmacologic correction of dominant-negative GH1 deficiency causing mutations. Clin Transl Sci 4:175-9
Hamid, Rizwan; Phillips 3rd, John A; Holladay, Cindy et al. (2009) A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II. J Clin Endocrinol Metab 94:4728-34
Mohamadi, Ali; Martari, Marco; Holladay, Cindy D et al. (2009) Mutation analysis of the muscarinic cholinergic receptor genes in isolated growth hormone deficiency type IB. J Clin Endocrinol Metab 94:2565-70
Solis, Amanda S; Peng, Rui; Crawford, J Barrett et al. (2008) Growth hormone deficiency and splicing fidelity: two serine/arginine-rich proteins, ASF/SF2 and SC35, act antagonistically. J Biol Chem 283:23619-26
Shariat, N; Holladay, C D; Cleary, R K et al. (2008) Isolated growth hormone deficiency type II caused by a point mutation that alters both splice site strength and splicing enhancer function. Clin Genet 74:539-45
Shariat, Nikki; Ryther, Robin C C; Phillips 3rd, John A et al. (2008) Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference. Endocrinology 149:580-6
Raskin, S; Petzl-Erler, M L; Phillips 3rd, J A et al. (2007) Cystic fibrosis gene variability in two southern Brazilian Amerindian populations: analysis of the deltaF508 mutation and the KM19 and XV2C haplotypes. Hum Biol 79:79-91
Hayashi, Yoshitaka; Kamijo, Takashi; Yamamoto, Michiyo et al. (2007) A case with isolated growth hormone deficiency caused by compound heterozygous mutations in GH-1: a novel missense mutation in the initiation codon and a 7.6kb deletion. Growth Horm IGF Res 17:249-53
Cogan, Joy D; Phillips 3rd, John A (2006) New methods in genetic diagnosis including prenatal diagnosis. Pediatr Endocrinol Rev 3 Suppl 3:424-33; discussion 434-6
Ryther, R C C; Flynt, A S; Phillips 3rd, J A et al. (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5-11

Showing the most recent 10 out of 54 publications